Board Meeting
Hamps Bio Board Meeting Intimation
Hamps Bio will hold a Board meeting on November 6, 2026, to consider unaudited standalone and consolidated financial results for the half year ended September 30, 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
6
Neutral
5
Bullish
3
Bearish
7
Neutral
13
Bullish
26
Bearish
1
Neutral
8
Bullish
23
Bearish
1
Neutral
8
Bullish
23
Bearish
1
Neutral
8
Bullish
23
Bearish
1
Neutral
8
Bullish
23
Agricultural Food & other Products
Other Agricultural Products
22 Cr
High Risk
-30.0
29.1
—
2.7
26.58
13.36
Sales CAGR
Profit CAGR
ROE
ROCE
Upcoming Result Date: Nov 05, 2026
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Hamps Bio Limited (HAMPS) is currently trading at 25.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Hamps Bio Limited is a company focused on ethical marketing and distribution of pharmaceutical and FMCG products, including pharma formulations and freeze-dried food items. The company was originally incorporated as a private entity in 2007 and transitioned to a public limited company in 2023, planning an IPO to expand its equity base. It operates a widespread distribution network with over 50 distributors and e-commerce platforms, selling pharmaceutical products in 8 Indian states and freeze-dried products in several countries. The company has diversified its offerings by launching an FMCG division, focusing on freeze dried and frozen products, under its brand 'FzyEzy' since 2017. Hamps Bio Limited's presence in the pharmaceutical industry is built through strategic partnerships with WHO GMP approved contract manufacturers, ensuring quality in its distributed products.
Over the past 52 weeks, Hamps Bio Limited has traded between a low of ₹13.36 and a high of ₹26.58. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Hamps Bio Limited has a market capitalization of approximately 22.22. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Hamps Bio Limited’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -30.03 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 22.22 Cr, Hamps Bio Limited is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Hamps Bio Limited operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Hamps Bio Limited is -30.03. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.